EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars
About author
You might also like
EU approves new drug for locally advanced basal cell cancer
Swiss multinational pharmaceutical company, Novartis announced today that the European Commission has approved its new drug, Odomzo for the treatment of adult patients with locally advanced basal cell carcinoma (cancer)
NAIP urges FG to build pharmaceutical production plants
Commences Annual Conference tomorrow Towards its effort to ensure a strategic re-positioning of the Nigerian Pharmaceutical Industry to attract more innovations and churns out competitive products for the international market
NAFDAC raises alert over fake anti-hypertension drug
ABUJA – The National Agency for Food, Drug Administration and Control has alerted the public on the circulation of a fake anti-hypertensive drug. NAFDAC’s Director General, Prof. Moji Adeyeye, in a
0 Comments
No Comments Yet!
You can be first to comment this post!